AI in Drug Discovery — Market Size and 2034 Forecast
OVERVIEWMarket analysis projects significant growth in AI-enabled drug discovery platforms through 2034, driven by pharma investment in accelerating lead identification and reducing development timelines. Key market drivers: rising R&D costs, pressure to address drug discovery bottlenecks, and proven AI capabilities in molecular simulation and target identification. Leading players include established pharma companies and specialized biotech startups. The market trajectory suggests AI will become standard in pharmaceutical development workflows, though clinical validation gaps and regulatory uncertainty remain challenges to widespread adoption. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.